BR112018011663A2 - toxina botulínica para distúrbios primários de humor e afetivos usando neurotransmissor - Google Patents

toxina botulínica para distúrbios primários de humor e afetivos usando neurotransmissor

Info

Publication number
BR112018011663A2
BR112018011663A2 BR112018011663A BR112018011663A BR112018011663A2 BR 112018011663 A2 BR112018011663 A2 BR 112018011663A2 BR 112018011663 A BR112018011663 A BR 112018011663A BR 112018011663 A BR112018011663 A BR 112018011663A BR 112018011663 A2 BR112018011663 A2 BR 112018011663A2
Authority
BR
Brazil
Prior art keywords
neurotransmitter
botulinum toxin
affective disorders
disorders
primary mood
Prior art date
Application number
BR112018011663A
Other languages
English (en)
Portuguese (pt)
Inventor
Borodic Gary
Acquadro Martin
Original Assignee
Revance Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/966,759 external-priority patent/US20160095908A1/en
Application filed by Revance Therapeutics Inc filed Critical Revance Therapeutics Inc
Publication of BR112018011663A2 publication Critical patent/BR112018011663A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
BR112018011663A 2015-12-11 2016-12-09 toxina botulínica para distúrbios primários de humor e afetivos usando neurotransmissor BR112018011663A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14/966,759 US20160095908A1 (en) 2005-06-14 2015-12-11 Botulinum Toxin for Primary Disorders of Mood and Affect using Neurotransmitter CNS imaging Studies
PCT/US2016/065898 WO2017100624A1 (en) 2015-12-11 2016-12-09 Botulinum toxin for primary disorders of mood and affect using neurotransmitter

Publications (1)

Publication Number Publication Date
BR112018011663A2 true BR112018011663A2 (pt) 2018-12-04

Family

ID=59013649

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018011663A BR112018011663A2 (pt) 2015-12-11 2016-12-09 toxina botulínica para distúrbios primários de humor e afetivos usando neurotransmissor

Country Status (13)

Country Link
EP (1) EP3386538A4 (es)
JP (1) JP2019504824A (es)
KR (1) KR20180093983A (es)
CN (1) CN109069609A (es)
AU (1) AU2016366428A1 (es)
BR (1) BR112018011663A2 (es)
CA (1) CA3007816A1 (es)
CO (1) CO2018007096A2 (es)
IL (1) IL259825A (es)
MX (1) MX2018007105A (es)
RU (1) RU2018125034A (es)
SG (1) SG11201804840SA (es)
WO (1) WO2017100624A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021137667A1 (ko) * 2019-12-30 2021-07-08 주식회사 에이티지씨 보툴리눔 신경독소를 포함하는 파킨슨병 치료용 조성물 및 이를 이용한 파킨슨병 치료 방법
CN114384185A (zh) * 2022-01-20 2022-04-22 北京航空航天大学 用于检测γ-氨基丁酸含量的试剂在制备诊断静脉流出障碍性疾病的试剂盒中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8734810B2 (en) * 2003-10-29 2014-05-27 Allergan, Inc. Botulinum toxin treatments of neurological and neuropsychiatric disorders
US8609112B2 (en) * 2003-10-29 2013-12-17 Allergan, Inc. Botulinum toxin treatments of depression
US20070264373A1 (en) * 2004-01-26 2007-11-15 Ian Carroll Toxin Induced Sympathectomy
US20100266638A1 (en) * 2004-02-26 2010-10-21 Allergan, Inc. Headache treatment method
US7655244B2 (en) * 2005-02-01 2010-02-02 Allergan, Inc. Targeted delivery of botulinum toxin for the treatment and prevention of trigeminal autonomic cephalgias, migraine and vascular conditions
US8926991B2 (en) * 2005-06-14 2015-01-06 Botulinum Toxin Research Associates, Inc. Botulinum toxin and the treatment of primary disorders of mood and affect
US20070218084A1 (en) * 2005-12-30 2007-09-20 Fondazione Pierfranco E Luisa Mariani- Onlus Method for the Mapping of the Epileptogenic Focus in the Pre-Surgical Evaluation of Patients with Intractable Epilepsy
WO2008024371A2 (en) * 2006-08-21 2008-02-28 Prexa Pharmaceuticals, Inc. Multimediator transporter inhibitors for use in treatment of central nervous system disorders
WO2010013495A1 (ja) * 2008-07-31 2010-02-04 財団法人化学及血清療法研究所 高度精製ボツリヌス毒素治療剤を有効成分として含有する薬学的組成物およびその利用
US9393291B2 (en) * 2012-04-12 2016-07-19 Botulinum Toxin Research Associates, Inc. Use of botulinum toxin for the treatment of cerebrovascular disease, renovascular and retinovascular circulatory beds
US9480731B2 (en) * 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations

Also Published As

Publication number Publication date
RU2018125034A3 (es) 2020-04-15
RU2018125034A (ru) 2020-01-13
KR20180093983A (ko) 2018-08-22
CA3007816A1 (en) 2017-06-15
MX2018007105A (es) 2018-09-07
CN109069609A (zh) 2018-12-21
EP3386538A1 (en) 2018-10-17
CO2018007096A2 (es) 2018-11-22
EP3386538A4 (en) 2019-07-17
IL259825A (en) 2018-07-31
SG11201804840SA (en) 2018-07-30
AU2016366428A1 (en) 2018-06-28
WO2017100624A1 (en) 2017-06-15
JP2019504824A (ja) 2019-02-21

Similar Documents

Publication Publication Date Title
BR112017017286A2 (pt) protease de cisteína
BR112017017284A2 (pt) protease de cisteína
BR112018010464A2 (pt) formulações farmacêuticas tópicas para tratar condições inflamatórias relacionadas
BR112018013065A2 (pt) composições e métodos para o tratamento de hemoglobinopatias
CO2017005034A2 (es) Tratamiento de convulsiones con fosfatasa alcalina recombinante
BR112018004620A2 (pt) moduladores da expressão de kras
BR112018070133A2 (pt) dispersão, uso desta e método para a inativação fotodinâmica de micro-organismos
BR112017008938A2 (pt) protease inteína-modificada, cassete de expressão, composição, produto de cuidados domésticos, método de regular a atividade de protease e método de armazenar uma protease em uma mistura
NI201600071A (es) Compuestos de inhibidor de autotaxina
BR112019006160A2 (pt) composições e métodos para o tratamento das condições oftálmicas
CR20140020A (es) Compuestos inhibidores de metaloenzimas
BR112017005693A2 (pt) método para tratar e/ou prevenir uma doença hepática, e, composição farmacêutica.
CR20170011A (es) Compuestos de heteroarilo para la inhibición de cinasa
EA201791874A1 (ru) Фторированные ингибиторы лизилоксидазоподобного фермента-2 и их применение
BR112015019995A2 (pt) Combinação terapêutica envolvendo anticorpos contra claudina 18.2 para tratamento de câncer
CR20170219A (es) Inhibidores del bromodominio
BR112019001039A2 (pt) composição para uso no tratamento de transtorno depressivo maior
BR112018003526A2 (pt) métodos de tratamento de doenças inflamatórias
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
BR112018000776A2 (pt) métodos para tratamento de câncer usando apilimod
MX2019002190A (es) Uso de pridopidina para tratar distonías.
BR112017025263A2 (pt) método para o tratamento de doença neurológica
BR112017003644A2 (pt) métodos de tratamento de distúrbios do sono e para regular produção de melatonina.
BR112017008097A2 (pt) método para tratar condições oculares
MX2017010654A (es) Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estres.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2700 DE 04-10-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.